MIV Therapeutics to Hold Annual Shareholder Meeting on Thursday, August 24; Company Officers to Review Past Milestone Achievements and Business Initiatives for Coming Year.

ATLANTA -- MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, will hold its annual general shareholder meeting on August 24, 2006, at the Company's offices in Vancouver.

At the meeting, MIVT leadership will discuss its business and scientific milestones achieved in its last fiscal year. Management will also outline key strategic initiatives, including its plans to advance its proprietary biocompatible coating programs toward human clinical trials.

"I'm looking forward to telling shareholders about the many encouraging accomplishments and independent validations that have strengthened MIVT during the past year," said Alan Lindsay, CEO of MIVT. "We have seen remarkable progress and we continue to use our scientific successes to further develop our business initiatives to commercialize our unique HAp coatings for use on vascular stents as well as other medically needed applications such as our recently announced plans to develop breakthrough biocompatible coating technology for products used in the $23 billion orthopedics device market."

Recent MIVT milestones and industry news affecting MIVT includes the following:

--A recent independent study into the use of HAp in vascular applications, conducted at the University of Sienna in Sienna, Italy, and published in the prestigious international Journal of Biomedical Materials Research, confirmed HAp technology as an exceedingly safe and potentially superior alternative to existing polymer-based, drug-coated stents now in use around the world.

--A growing body of both basic scientific evidence -- as well as real-world treatment practices at leading cardiac care institutions -- that further validates the Company's core technology and business strategy to make a safer generation of coronary stents based on its proprietary bio-friendly stent coatings.

--SagaX, a wholly-owned subsidiary of MIVT, has filed three new patents with the U.S. Patent Office related to a proprietary implantable filtration device designed to help prevent common stroke complications during and after a range of common invasive heart procedures.

--Appointment of nationally ranked Wall Street medical device industry analyst and industry authority Dr. Mark Landy as Company President.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogycapital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.